Observed Signal · Feb 6, 2026 · Brand & Market Positioning · Source: Feedspot/RSS · Impact: 2/5 · Sentiment: Neutral
Embrace Wegovy: Novo Nordisk's Bold Super Bowl Debut
Novo Nordisk will air its first-ever Super Bowl commercial to promote Wegovy now being available as a pill and to reduce stigma around taking the drug. The spot, titled “A New Way to Wegovy,” features celebrities including Kenan Thompson, DJ Khaled, Danielle Brooks, Ana Gasteyer, John C. Reilly and Danny Trejo, and aims to normalize conversations about GLP-1 medications. The ad will run nationally in the third quarter of Super Bowl 60 on Feb. 8. Novo Nordisk developed the campaign with M+C Saatchi and production company O Positive, with media buying by CMI Media Group/WPP Media. The placement is part of a broader trend of pharma promoting GLP-1 drugs during the Big Game; Eli Lilly and direct-to-consumer seller Ro are also running GLP-1 messaging. A KFF survey cited in the piece found 12% of U.S. adults now use a GLP-1 drug, up from 6% two years earlier.
A major advertiser (Novo Nordisk) buying Super Bowl inventory signals rising pharma presence and direct-to-consumer marketing for GLP-1 drugs during premium TV moments, relevant for media buyers, brand-safety and inventory demand — but it is not industry-shifting on its own.
Track O Positive Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your free Explorer workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Novo Nordisk will air its first-ever Super Bowl ad promoting Wegovy as a pill.
- The ad, “A New Way to Wegovy,” features Kenan Thompson, DJ Khaled, Danielle Brooks, Ana Gasteyer, John C. Reilly and Danny Trejo.
- The commercial will run nationally during the third quarter of Super Bowl 60 on Feb. 8.
- Campaign partners include creative/agency M+C Saatchi, production company O Positive, and media buying by CMI Media Group/WPP Media.
- A KFF survey found 12% of U.S. adults use a GLP-1 drug, up from 6% two years ago.
Connected Companies & Entities
4 Entities mappedOntology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Eli Lilly Debuts GLP-1 Ad Targeting Medicare Enrollees
Eli Lilly and Wieden+Kennedy Portland premiered a film called “A Life Covered” to raise awareness among Medicare Part D enrollees about newly available coverage for certain GLP-1 weight-management medications under a CMS demonstration called the Medicare GLP-1 Bridge. The ad — credited to directors Kwedar and Bentley, shot by Linus Sandgren and scored by Caroline Shaw — aims to inform seniors about access and cost (noted as $50/month under the demonstration). Lilly positioned the spot as a consumer awareness effort for patients and seniors; the campaign continues a multi-year partnership between Lilly and Wieden+Kennedy.
Wieden + Kennedy Spot Challenges Obesity Stigma for Lilly
Lilly Deutschland has launched a new emotional advertising campaign to combat prejudice against people with obesity. The spot, created by Wieden + Kennedy, features a father leaving an apology voicemail for his adult daughter, acknowledging he failed to support her because he believed weight loss was just a matter of willpower. The campaign is part of the broader #gutbehandelt initiative, which has run since 2024, and aims to educate that obesity is a chronic but treatable disease. It encourages affected individuals to seek medical help and calls for respectful, understanding treatment within society and the healthcare system. The campaign is supported by Spark Foundry Germany for media, DocCheck for social media and influencer relations, and Fischer-Appelt for PR. It launched on September 1, 2026, across TV, social media, out-of-home, and pharmacies in Germany.
Novo Nordisk Sues Eli Lilly Over Advertising Claims
Danish drugmaker Novo Nordisk has filed a lawsuit against U.S. rival Eli Lilly in a federal court in New Jersey, accusing the company of unfair competition and misleading advertising in nationwide campaigns for obesity and diabetes medicines. Novo Nordisk says Eli Lilly compared the highest approved doses of Lilly’s drugs with lower doses of Novo Nordisk’s Wegovy and Ozempic while omitting mention of newly approved higher Wegovy doses. Novo Nordisk seeks a court order to stop the campaign, a public correction and damages including profits from the advertising. The dispute occurs amid intense competition in the obesity drug market, which analysts estimate could exceed $100 billion by 2030.
Track Real-Time Market Signals & Shifts
Set up custom watchlists to receive automated, evidence-grounded executive digests whenever material signals or shifts occur across your tracked landscape.